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PERFORMANCES OF HTLV SEROLOGICAL TESTS IN DIAGNOSING HTLV INFECTION IN
HIGH-RISK POPULATION OF SÃO PAULO, BRAZIL
Fabrício JACOB(1), Elizabeth de los SANTOS-FORTUNA(1), Raymundo Soares AZEVEDO(2) & Adele CATERINO-DE-ARAUJO(1)
SUMMARY
Testing problems in diagnosing human T-lymphotropic virus (HTLV) infection, mostly HTLV-II, have been documented in
HIV/AIDS patients. Since December 1998, the Immunology Department of Instituto Adolfo Lutz (IAL) offers HTLV-I/II serology
to Public Health Units that attend HTLV high-risk individuals. Two thousand, three hundred and twelve serum samples: 1,393
from AIDS Reference Centers (Group I), and 919 from HTLV out-patient clinics (Group II) were sent to IAL for HTLV-I/II
antibodies detection. The majority of them were screened by two enzyme immunoassays (EIAs), and confirmed by Western Blot
(WB 2.4, Genelabs). Seven different EIA kits were employed during the period, and according to WB results, the best performance
was obtained by EIAs that contain HTLV-I and HTLV-II viral lysates and rgp21 as antigens. Neither 1st and 2nd, nor 3rd generation
EIA kits were 100% sensitive in detecting truly HTLV-I/II reactive samples. HTLV-I and HTLV-II prevalence rates of 3.3% and
2.5% were detected in Group I, and of 9.6% and 3.6% in Group II, respectively. High percentages of HTLV-seroindeterminate WB
sera were detected in both Groups. The algorithm testing to be employed in HTLV high-risk population from São Paulo, Brazil,
needs the use of two EIA kits of different formats and compounds as screening, and because of high seroindeterminate WB, may
be another confirmatory assay.
KEYWORDS: Human T-lymphotropic virus type I and II (HTLV-I and HTLV–II); Serology; Enzyme immunoassay (EIA);
Diagnosis; Performance; High-risk population.
INTRODUCTION
Brazil has been pointed as the country with the highest absolute
number of HTLV-I/II-seropositive individuals in the world, and shows
heterogeneous distribution of HTLV-I and HTLV-II depending on the
ethnic background of individuals and its geographic location4,12.
A variety of clinical conditions has been associated with HTLV-I,
and more recently with HTLV-II, making the accurate diagnosis of
such viruses important to prompt attend and counsel the HTLV-infected
individuals12.
Although among endemic populations vertical and sexual
transmission seems to be the most important means of virus
transmission/acquisition, blood was considered a vehicle of HTLV-I/
II transmission mostly among intravenous drug users (IVDU), infected
with HIV-12,3,5,6,9,12. In 1993, HTLV serology became mandatory in
Blood Centers of Brazil, and more recently, the Ministry of Health
recommended two algorithms to be used in Blood Donation Services
and Public Health Laboratories of this country8. In Blood Centers, serum
samples were screened for the presence of HTLV-I/II-specific antibodies
using one enzyme immunoassay (EIA) which contains selected antigens
for HTLV-I and HTLV-II. Reactive or indeterminate sera were re-tested
in duplicate on the same EIA; samples that resulted seroreactive or
seroindeterminate exclude its blood donation. Concerning Public Health
Laboratories, after HTLV-I/II EIA screening, seroreactive samples were
confirmed by immunofluorescence (IFA) or Western blot (WB) assays8.
Previous studies have shown serologic testing problems in
diagnosing HTLV, mostly HTLV-II infection among HIV/AIDS patients
from Brazil2-5,10, independently of the test algorithm employed, and
the polymerase chain reaction (PCR) and IFA were suggested as HTLV
confirmatory assays3,5-7,10,12.
The Immunology Department of Instituto Adolfo Lutz offers HTLV-
I/II serology to Public Health Units since December 1998. Instituto
Adolfo Lutz (IAL) is a Central Public Health Laboratory of São Paulo
City, which is reference of several infectious diseases, including HIV/
AIDS. Its staff is composed by scientific researchers along with
technical personal capable of doing, controlling, and analyzing routine
procedures for diagnosis. Serological kits for routine purpose were
acquired according to supply and demand or by convenience, and the
test algorithm used for HTLV-I/II antibodies detection includes two
EIAs of different formats and compounds as screening, and Western
Blot (WB) as confirmatory test.
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The present study had the aim to analyze the results obtained from
the HTLV-serological routine of IAL, showing the attended population,
the diversity of available EIA kits and its performances according to
WB confirmatory results, and the prevalence rates of HTLV-I and HTLV-
II antibodies in high-risk population from São Paulo, Brazil.
MATERIALS AND METHODS
From December 1998 to March 2006, 2,312 serum samples from
São Paulo City and vicinity were sent to IAL for HTLV-I/II serology:
1,393 (60.25%) came from AIDS Reference Centers (411 from females
and 982 from males, Group I), and 919 (39.75%) sera were from HTLV
out-patient clinics (381 females and 539 males, Group II). The
population aged 21 to 50 years with a peak of 31 to 40 years. Four-
hundred fifty-five samples (19.68%) were screened for the presence of
HTLV-I/II specific antibodies by only one EIA kit, and 1,857 (80.32%)
were tested by two HTLV-I/II EIA kits. During the period, seven
different EIA kits were employed, and the reactions were conducted
according to manufacturer instructions. Serum samples that resulted
OD/cutoff ≥ 1.0 were considered reactive for HTLV-I/II antibodies.
Sera that resulted reactive on at least one EIA, were submitted to WB
test, and the results were interpreted according to the stringent criteria
indicated by the manufacturer (WB HTLV 2.4, Genelabs® Diagnostics).
HTLV-I/II serological results were collected and analyzed using
the Minitab Program (MINITAB® Release 14.1 © 1972-2003 Minitab
Inc.). For the calculation of sensitivity, specificity, and efficiency it
was considered only the positive or negative results on WB 2.4. To
conduct the present study, ethical institutional approval was obtained.
RESULTS
After HTLV-I/II EIA screening, 461 sera that resulted reactive on
at least one EIA were submitted to WB 2.4 assay: 94 out of 455 screened
on one EIA, and 367 out of 1,857 tested on two EIAs. The results
obtained on WB 2.4 of each Group as well the general results obtained
were presented in Table 1. Antibodies to HTLV-I and HTLV-II were
detected in both Groups, although HTLV-I was more prevalent among
individuals of Group II. High percentages of HTLV-indeterminate WB
results were observed in both Groups of individuals (Table 1).
Using WB 2.4 as the gold standard for HTLV-seroreactive samples,
the sensitivity, specificity, and efficiency of EIA kits were calculated
and presented in Table 2. The overall analysis of EIAs disclosed the
best performance of the EIA kit which employed HTLV-I and –II viral
lysates plus rgp21 (Vironostika HTLV-I/II, BioMerieux**).
As shown in Table 3, 19 (11.45%) samples that resulted discordant
on EIA analysis, confirmed HTLV-seropositivity on WB 2.4, and
pointed out the need of using two EIAs for confirming HTLV infection
in high risk population of São Paulo. Indeed, this finding stated that
EIA kits which use recombinant proteins/synthetic peptides as antigen
are more sensitive than the other kits (see column 1 in Table 3); on the
other hand, EIA kits that employ viral lysates plus recombinant antigens
were more specific (see column 3 in Table 3).
DISCUSSION
The present study disclosed the performance of HTLV serological
tests used in the routine procedure of IAL, a Public Health Laboratory
from São Paulo, Brazil, and pointed some conditions that could affect
the reliability of HTLV serological diagnosis in high-risk population
of this geographic area. Initially, the HTLV EIA kits employed on
serodiagnosis of HTLV-I/II were obtained by supply and convenience,
and during the period analyzed, seven different kits were used as
screening. Some EIAs changed manufacturer, others disappeared from
commerce, and finally some EIA kits improved antigen composition
adding recombinant proteins and/or synthetic peptides from HTLV-I
and -II (data not shown). Although these changes, neither 1st and 2nd
nor 3rd generation EIA kits were 100% sensitive in detecting HTLV-I/
II antibodies in such population. As shown in Table 3, 11.45% of sera
that resulted discordant on EIAs resulted WB 2.4 positive. Thus, the
use of only one EIA kit as screening as recommended by the Ministry
Table 1
 Prevalence rates of HTLV-I and HTLV-II antibodies in high-risk population of
São Paulo according to EIA confirmed by WB 2.4
EIA
Results Group I Group II Total
n (%) n (%) n (%)
HTLV-I 46 (3.30) 88 (9.58) 134 (5.80)
HTLV-I/II 1 (0.07) 2 (0.22) 3 (0.13)
HTLV-II 35 (2.51) 33 (3.59) 68 (2.94)
HTLV 1 (0.07) 13 (1.41) 14 (0.61)
Indeterminate 75 (5.38) 88 (9.58) 163 (7.05)
Negative 1,235 (88.66) 695 (75.63) 1,930 (83.48)
Total 1,393 (100.00) 919 (100.00) 2,312 (100.00)
Group I: sera from individuals attended at AIDS Reference Centers of São Paulo.
Group II: sera from individuals seen at HTLV out-patients clinics of São Paulo.
Table 2
Sensitivity, specificity, and efficiency of the HTLV-I/II EIA kits in detecting
HTLV-specific antibodies in relation to WB 2.4, on high-risk population
of São Paulo
Sensitivity Specificity Efficiency
(%) (%) (%)
1st EIA set (n = 1,071)
V* (n = 194) 71.4 100.0 78.9
HB (n = 182) 80.9 33.3 70.4
P (n = 695) 98.4 44.4 82.4
2nd EIA set (n = 925)
V**(n = 660) 95.8 70.0 90.2
HE (n = 265) 90.9 83.3 86.9
3rd EIA set (n = 2,173)
O (n = 454) 94.4 46.7 80.4
M (n = 1,719) 98.2 42.6 83.7
n: number of serum samples analyzed; 1st EIA set: EIA kits that use HTLV-I/II
viral lysates as antigen (Hemobio HTLV-I/II HBK 424, EMBRABIO; Platelia®
HTLV-I New, Bio-Rad; Vironostika® HTLV-I/II, Organon Teknika Corp.*); 2nd
EIA set: EIA kits that employ HTLV-I/II viral lysates plus recombinant antigens
(Hemagen® HTLV-I + HTLV-II, Hemagen Diagnósticos Com. Ltda; Vironostika
HTLV-I/II, BioMerieux**); 3rd EIA set: EIA kits that contain HTLV-I/II
recombinant antigens/synthetic peptides as antigens (Murex HTLV-I+II, Murex
Biotech; Ortho® HTLV-I/HTLV-II, Ortho Clinical Diagnostics Inc.).
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of Health of Brazil8, may account for the lacking of truly HTLV-I/II-
infected patients. In accordance with this hypotheses, several years
ago a group of researchers from San Francisco, California, described
HTLV-false-negative EIA results on plasma samples from 50 injection
drug users (IDU) HTLV-II-infected. Although these problem specimens
resulted WB-indeterminate on two commercial WB kits, they were
confirmed as HTLV-II-infected by IFA and PCR7. That work and the
present study make possible to speculate that during the period of which
only one EIA screening was employed in high-risk population from
São Paulo, some HTLV-infected patients could be missing. We do not
know the risk factor for acquiring retroviruses of patients, but since
sera from Group I came from AIDS Reference Centers, surely IVDU
would be included. Indeed, we may not exclude the same risk factor
among some patients from Group II.
At present, although 3rd generation EIA kits showed high sensitivity
in detecting HTLV-I/II positive sera, kits of 2nd generation showed the
best performance when used on high-risk population from São Paulo
(Tables 2 and 3); this result contrast with a previous study of HIV/
AIDS patients conducted by some of us in another region of Brazil,
(Londrina, Paraná) of which 3rd generation EIA kit showed the best
result on HTLV-I/II serological screening10. On the other hand, in
agreement with the present results, several years ago, an EIA kit that
employed HTLV-I and HTLV-II viral lysates (ELISA HTLV-I/II,
EMBRABIO, BR) presented the best results on high-risk population
of São Paulo, Brazil5. Interestingly, both studies employed the PCR
for confirming the presence of HTLV-I and HTLV-II provirus in blood,
strategy that could not be used in the present study, since the fluid sent
for routine purpose was sera, and no cells were available, which were
necessary for searching HTLV provirus in blood12.
The source of missing HTLV-seropositive samples in high-risk
population may be the immunosuppression and/or seroconversion
period of which these patients were undergone. In fact, previous studies
showed that HIV/HTLV-II co-infected patients were enable to mount
and/or maintain an appropriate level of HTLV-II antibodies, particularly
in advanced stages of HIV infection1,12,14. We do not know the real
immunological status of patients but we could speculate
immunosuppression as the cause of serological lack, mostly in patients
of Group I. Of note, we could not discard the same immunological
suppression among patients from Group II, since their HIV status was
unknown.
Interestingly, patients from Group II presented higher proportion
of HTLV-I-seropositive results (Column 2, Table1), and this finding
could be related to clinical manifestations associated to HTLV-I seen
at HTLV out-patient clinics, such as adult T cell leukemia/lymphoma
(ATL), and tropical spastic paraparesis or HTLV-associated myelopathy
(TSP/HAM)12. Although medical requests for HTLV-I/II serology do
not contain clinical and epidemiological data of such patients, in several
ocasions the serology requests were signed by hematologists and
neurologists. Of note, TSP/HAM simile diagnosis was recently reported
in São Paulo, Brazil, in HIV/HTLV-II co-infected patients11, and
although HTLV-II solely were associated with an increased incidence
of pneumonia and bronchitis, arthritis, and few cases of cutaneous
lymphoma, when associated with HIV may alter the levels of CD4+
and CD8+ lymphocytes, and under antiretroviral therapy may increase
HTLV-II proviral load13.
In conclusion, the present study emphasizes the need of two EIAs
of diverse antigens and formats to be used in high risk population from
São Paulo, Brazil, and confirms high number of HTLV-
seroindeterminate samples which will be analyzed apart.
RESUMO
Desempenho de testes sorológicos para o diagnóstico de infecção
por HTLV em população de alto-risco de São Paulo, Brasil
Problemas nos testes diagnósticos de infecção pelos vírus
linfotrópicos de células T humanas (HTLV), principalmente HTLV-II,
têm sido observados em pacientes com HIV/Aids. Desde Dezembro
de 1998, a Seção de Imunologia do Instituto Adolfo Lutz (IAL) oferece
a sorologia para HTLV-I/II para Serviços de Saúde Pública que atendem
populações consideradas de risco para esta infecção. Duas mil trezentas
e doze amostras de soro: 1.393 de Centros de Referência em Aids
(Grupo I) e 919 de Clínicas de Especialidade em HTLV (Grupo II)
foram encaminhadas para o IAL para a pesquisa de anticorpos anti-
HTLV-I/II. A maioria delas foram testadas por dois ensaios
imunoenzimáticos (EIAs) e confirmadas por Western Blot (WB 2.4,
Genelabs). Sete kits diferentes de EIAs foram empregados durante o
período e de acordo com os resultados do WB a melhor performance
foi obtida com os EIAs que continham lisado viral dos HTLV-I e -II e
a rgp21 como antígenos. Nenhum kit de EIA de 1a, 2a ou 3a geração foi
100% sensível para detectar todas as amostras verdadeiramente HTLV-
I/II reagentes. A prevalência de HTLV-I e HTLV-II, respectivamente,
Table 3
Number and percentages of samples tested by two EIA kits (n = 367) and results obtained on WB 2.4 analysis, according to the set of EIA kits employed as screening
EIA set (results) WB 2.4
Positive Indeterminate Negative Total
n (%) n (%) n (%) n (%)
Discordant 19 (11.45) 93 (56.02) 54 (32.53) 166 (100.00)
1st (-) vs 3rd (+) 9 (18.00) 24 (48.00) 17 (34.00) 50 (100.00)
1st (+) vs 3rd (-) 3 (5.45) 35 (63.65) 17 (30.91) 55 (100.00)
2nd (-) vs 3rd (+) 5 (15.15) 13 (39.39) 15 (45.45) 33 (100.00)
2nd (+) vs 3rd (-) 2 (7.14) 21 (75.00) 5 (17.86) 28 (100.00)
Concordant (+) 153 (76.12) 44 (21.89) 4 (1.99) 201 (100.00)
WB: WB HTLV 2.4, Genelabs® Diagnostics.
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foi de 3,3% e 2,5% no Grupo I e de 9,6% e 3,6% no Grupo II. Em
ambos os Grupos, foram detectadas altas percentagens de soros com
padrão indeterminado no WB. O algoritmo de testes sorológicos para
ser usado em população de alto risco para HTLV de São Paulo, Brasil,
necessita de dois kits EIAs de princípios e composição diferentes para
a triagem sorológica e, pelo elevado número de WB indeterminado,
talvez de um outro teste confirmatório.
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